The US Food and Drug Administration’s final guidance document on Diversity Action Plans (DAPs) should carve out devices that are equally effective across demographics, trade group the Medical Device Manufacturers Association said in a recent public comment.
The comment was one of about 140 submitted in response to June’s draft guidance document on improving enrollment of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?